
Enrico Di Cera, M.D.
Alice A. Doisy Professor & Chair
Structural enzymology of coagulation factors.
Research Interests
Our research builds upon 30+ years of continuously funded work on the enzymology and structural biology of proteins involved in blood coagulation and on mechanisms of ligand binding.
We are interested in the structural enzymology of proteins responsible for blood coagulation, with the goal of unraveling their molecular architecture and mechanisms. Our approach uses a combination of conventional (rapid kinetics, protein engineering, X-ray crystallography) and innovative (smFRET, cryo-EM) biophysical techniques.
We currently focus on the structure, function and regulation of prothrombin (HL049413), protein C (HL139554) and factor V (HL147821). Also of interest is the molecular basis of protease specificity.
Research Highlights

Cryo-EM structures of human coagulation factors V and Va. Ruben EA, Rau MJ, Fitzpatrick JAJ, Di Cera E. Blood 137(22):3137, 2021.

Cryo-EM structure of the prothrombin-prothrombinase complex. Ruben EA, Summers B, Rau MJ, Fitzpatrick JAJ, Di Cera E. Blood 139(24):3463, 2022.

Cryo-EM structure of coagulation factor Va bound to activated protein C. Mohammed BM, Basore K, Di Cera E. Blood 145(26):3166, 2025.
Recent Publications
Molecular mechanism of cleavage at R271 during prothrombin activation revealed by cryo-EM
Molecular mechanism of cleavage at R271 during prothrombin activation revealed by cryo-EM
The conversion of the inactive zymogen prothrombin to the active protease thrombin in the common pathway of the coagulation cascade is the molecular event responsible for the pathophysiology of hemostasis and thrombosis. The conversion entails two proteolytic cleavages at R320 and R271 by the prothrombinase complex composed of the enzyme factor Xa (fXa), the cofactor fVa, Ca2+ and phospholipids. A recent cryogenic electron microscopy (cryo-EM) structure revealed how cleavage at R320 generates the active intermediate meizothrombin in the first step of the activation pathway. Here we present the 3.8 Å resolution cryo-EM structure of a truncated form of meizothrombin (mzTDF1) bound to fVa and fXa that reveals how the second cleavage at R271 generates thrombin. The cleavage is brokered by molecular contacts that involve mostly the protease domains of mzTDF1 and fXa and largely validate the results from biochemical studies. The switch in cleavage site from R320 to R271 involves a significant reorientation rather than conformational transitions of the protease domain of mzTDF1 that moves the guanidinium group of R271 more than 20 Å into the primary specificity pocket of fXa. The findings complete the cryo-EM structural analysis of prothrombin activation along the meizothrombin pathway and advance our molecular understanding of a reaction critical to the pathophysiology of blood coagulation.
Structural determinants of protease-activated receptor 1 cleavage by activated protein C
Structural determinants of protease-activated receptor 1 cleavage by activated protein C
Activated protein C (APC) performs cytoprotective functions mediated by cleavage of the protease-activated receptor 1 (PAR1) in the presence of the endothelial protein C receptor and signaling through β-arrestin-2. APC cleaves PAR1 at R41 and R46, but the specificity of the reaction is low. In contrast, thrombin cleaves PAR1 at R41 only in a reaction that is independent of endothelial protein C receptor, producing a proinflammatory response mediated by signaling through G-protein intermediates and features high specificity. The molecular basis of this difference between APC and thrombin remains unknown.
Cryo-EM structure of coagulation factor Va bound to activated protein C
Cryo-EM structure of coagulation factor Va bound to activated protein C
Coagulation factor Va (FVa) is the cofactor component of the prothrombinase complex required for rapid generation of thrombin from prothrombin in the penultimate step of the coagulation cascade. In addition, FVa is a target for proteolytic inactivation by activated protein C (APC). Like other protein-protein interactions in the coagulation cascade, the FVa-APC interaction has long posed a challenge to structural biology and its molecular underpinnings remain unknown. A recent cryogenic electron microscopy (cryo-EM) structure of FVa has revealed the arrangement of its A1-A2-A3-C1-C2 domains and the environment of the sites of APC cleavage at R306 and R506. Here, we report the cryo-EM structure of the FVa-APC complex at 3.15 Å resolution in which the protease domain of APC engages R506 in the A2 domain of FVa through electrostatic interactions between positively charged residues in the 30-loop and 70-loop of APC and an electronegative surface of FVa. The auxiliary γ-carboxyglutamic acid and epidermal growth factor domains of APC are highly dynamic and point to solvent, without making contacts with FVa. Binding of APC displaces a large portion of the A2 domain of FVa and projects the 654VKCIPDDDEDSYEIFEP670 segment as a “latch,” or exosite ligand, over the 70-loop of the enzyme. The latch induces a large conformational change of the autolysis loop of APC, which in turn promotes docking of R506 into the primary specificity pocket. The cryo-EM structure of the FVa-APC complex validates the bulk of existing biochemical data and offers molecular context for a key regulatory interaction of the coagulation cascade.
Replacement of a single residue changes the primary specificity of thrombin
Replacement of a single residue changes the primary specificity of thrombin
Thrombin prefers substrates carrying Arg at the site of cleavage (P1) because of the presence of D189 in the primary specificity (S1) pocket but can also cleave substrates carrying Phe at P1. The structural basis of this property is unknown.
Another cryo-EM success: structure of FXIII
